Anti-African swine fever virus protein antibody and its use

Single-chain antibodies against African swine fever virus were screened through phage display technology, combined with African swine fever virus p30 protein, solving the detection problems in the existing technology, achieving high sensitivity and high specificity detection, and improving the detection of African swine fever virus Output rate and diagnostic accuracy.

CN118652329BActive Publication Date: 2024-12-06SHENZHEN BIOEASY BIOTECHNOLOGY CO LTD +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411155011.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-12-06
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

The existing technology cannot provide high specificity and high sensitivity of African swine fever virus-specific antibodies, which leads to difficulties in detecting and diagnosing African swine fever virus, especially in the high mortality rate of the strain, which causes huge harm to the global pig farming industry. .

Method used

Single-chain antibodies against African swine fever virus with strong biological activity and antigen binding ability were screened through phage display technology, and the heavy and light chain variable regions specifically bind to African swine fever virus p30 protein, and construct them for detection and diagnosis test agent.

Benefits of technology

High sensitivity and specificity detection of African swine fever virus have been achieved, which significantly improves the detection rate and reduces the detection cost, and provides a feasible solution for the high-precision detection and diagnosis of African swine fever virus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118652329B_ABST
    Figure CN118652329B_ABST
Patent Text Reader

Abstract

The present invention relates to a novel anti-African swine fever virus (ASFV) antibody and its use. The anti-ASFV antibody of the present invention exhibits high sensitivity and high specificity in specific binding to the p30 protein of the African swine fever virus, and thus can be used as a detection antibody for the African swine fever virus, providing a feasible solution for the high-precision clinical detection and diagnosis of the African swine fever virus and the prevention and control of the disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and in particular relates to an anti-African swine fever virus protein specific antibody and a use thereof. Background Art

[0002] African swine fever (ASF) is an acute and severe infectious disease caused by the African swine fever virus (ASFV) in pigs, characterized by fever and bleeding in various organs of the body. African swine fever infects domestic pigs and various wild boars, with a very high mortality rate (close to 100%), causing great harm to the global pig industry. There is no safe and effective vaccine for African swine fever. Internationally, African swine fever is mainly detected and diagnosed through etiological and serological methods. Since the introduction of African swine fever virus gene type II into my country in August 2018, it has had a profound impact on my country's pig industry due to the high mortality rate of the strain. At present, studies have shown that there are not only low-pathogenic type I strains in clinical practice, but also chimeric strains of type I and type II.

[0003] Therefore, there is a need in the art for an African swine fever virus-specific antibody with high specificity and sensitivity, so as to provide a feasible solution for the highly accurate clinical detection and diagnosis of African swine fever virus. Summary of the invention

[0004] The present invention is based on phage display technology, takes the p30 protein of African swine fever virus (ASFV) as the antigen protein, constructs a phage mouse immune library, and screens out anti-ASFV single-chain antibodies with biological activity and strong antigen binding ability, thereby obtaining the present invention.

[0005] In a first aspect of the present invention, an anti-African swine fever virus antibody is provided, the antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a heavy chain complementary determining region V having an amino acid sequence of SEQ ID NO: 1-3, respectively. H CDR1, V H CDR2 and V H CDR3, the light chain variable region includes a light chain complementary determining region V having an amino acid sequence of SEQ ID NO: 4-6, respectively. L CDR1, V L CDR2 and V L CDR3.

[0006] In a second aspect, a nucleic acid molecule is provided, which encodes the anti-African swine fever virus antibody described in the first aspect.

[0007] In the third aspect, a vector is provided, which comprises the nucleic acid molecule described in the second aspect.

[0008] In a fourth aspect, an expression cell is provided, which comprises the nucleic acid molecule described in the second aspect or the vector described in the third aspect.

[0009] In the fifth aspect, provided is the use of the anti-African swine fever virus antibody described in the first aspect in the preparation of a detection agent for detecting African swine fever virus.

[0010] In a sixth aspect, a method for detecting African swine fever virus is provided. The method is used for non-diagnostic purposes or diagnostic purposes, and comprises the step of using the anti-African swine fever virus antibody described in the first aspect.

[0011] In the seventh aspect, a kit for detecting African swine fever virus is provided, comprising the anti-African swine fever virus antibody described in the first aspect and instructions for use for guiding how to detect African swine fever virus.

[0012] In summary, the present invention screened out a new anti-African swine fever virus single-chain antibody based on phage display technology, which showed high sensitivity and high specificity for the African swine fever virus p30 protein, and could achieve more sensitive detection at nanogram concentrations, greatly improving the detection rate of African swine fever virus and reducing the detection cost, providing a feasible solution for high-precision detection and diagnosis of African swine fever virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] In order to more clearly illustrate the specific implementation of the present invention or the technical solution in the prior art, the drawings required for use in the specific implementation or the description of the prior art are briefly introduced below.

[0014] Figure 1 The PCR method is used to amplify V H and V L result.

[0015] Figure 2 The SDS-PAGE identification results of the induced expressed recombinant anti-African swine fever virus antibodies of the present invention are shown.

[0016] Figure 3 The binding activity of the recombinant anti-African swine fever virus antibody of the present invention to the p30 protein is shown.

[0017] Figure 4 The binding activity of the recombinant anti-African swine fever virus antibody of the present invention to p30 protein, p54 protein, p72 protein, porcine circovirus Cap protein and classical swine fever virus E2 protein is shown. DETAILED DESCRIPTION

[0018] Hereinafter, the present invention will be described in detail with reference to the accompanying drawings. It should be understood that the following description is only used to illustrate the present invention by way of example, and is not intended to limit the scope of the present invention. The scope of protection of the present invention shall be subject to the attached claims. In addition, those skilled in the art will understand that the technical solution of the present invention may be modified without departing from the spirit and purpose of the present invention. Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art.

[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter described herein belongs. Before describing the present invention in detail, the following definitions are provided for a better understanding of the present invention.

[0020] Where a numerical range is provided, such as a concentration range, a percentage range, or a ratio range, it is understood that each intervening value to one-tenth of the unit of the lower limit between the upper and lower limits of the range and any other stated or intervening values ​​in the stated range are included in the subject matter unless the context clearly dictates otherwise. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges, and such embodiments are also included in the subject matter, subject to any specifically excluded limit in the stated range. Where the stated range includes one or two limits, ranges excluding either or both of those included limits are also included in the subject matter.

[0021] In the context of the present invention, many embodiments use the expressions "comprising", "including" or "consisting essentially / mainly of..." The expressions "comprising", "including" or "consisting essentially / mainly of..." can usually be understood as open-ended expressions, indicating that it includes not only the elements, components, assemblies, method steps, etc. specifically listed after the expression, but also other elements, components, assemblies, method steps. In addition, in this article, the expressions "comprising", "including" or "consisting essentially / mainly of..." can also be understood as closed expressions in some cases, indicating that it only includes the elements, components, assemblies, method steps specifically listed after the expression, but does not include any other elements, components, assemblies, method steps. At this time, the expression is equivalent to the expression "consisting of..."

[0022] In order to better understand the present teachings and not to limit the scope of the present teachings, unless otherwise indicated, all numbers and other numerical values ​​used in the specification and claims indicating quantities, percentages or ratios should be understood as being modified by the term "about" in all cases. Therefore, unless otherwise indicated, the numerical parameters set forth in the following specification and the appended claims are approximate values, which may vary depending on the desired properties sought to be obtained. At a minimum, each numerical parameter should at least be interpreted in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0023] In the present invention, single chain Fv (scFv) is screened by phage display technology. The term "phage display technology" is an important molecular biology technology, which uses a modified phage as a vector to insert the selected gene fragment into the phage coat protein region, so that the exogenous polypeptide or protein is expressed and displayed on the phage surface, and then the phage expressing the specific exogenous polypeptide or protein is screened by affinity enrichment method, and finally the polypeptide / protein with specific binding properties is obtained, and gene cloning is realized. Compared with traditional hybridoma technology, phage display technology has a large library capacity, a wide range of screening types, and is easier to obtain highly active monoclonal antibodies against specific antigen epitopes. At the same time, the screening process is more time-saving, labor-saving, efficient and economical, which is conducive to screening specific binding antibodies.

[0024] As used herein, the term "single-chain antibody (scFv)" refers to a heavy chain variable region (V H ) and the light chain variable region (V L ) are connected to obtain a polypeptide fragment. scFv can be obtained by connecting the heavy chain variable region (V H ) and the light chain variable region (V L ) are connected to the C-terminus of the light chain variable region (V L ) and the heavy chain variable region (V H ) are connected to the C-terminus of the scFv by a connecting peptide. Generally speaking, the assembly order of scFv does not affect its characteristics. Single-chain antibody (scFv) is a fusion protein that retains the specificity of the original immunoglobulin to the antigen. The relative molecular mass of scFv is about 27kDa, which is only one-sixth of the complete antibody. This brings advantages such as strong intratumor penetration, rapid degradation in the blood, and small negative feedback in the human body, which also lays the foundation for the clinical application of scFv.

[0025] V H and V LThe variable regions can be further subdivided into regions of high variability, called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). For each heavy or light chain, its variable region each contains three CDRs, namely CDR1, CDR2, and CDR3. H and V L It consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. H and V L ) form antigen binding sites respectively. scFv retains the complete antigen binding site, reduces the size of antibody molecules, and also has the characteristics of good permeability, low immunogenicity and strong penetration. The rules for assigning amino acids to various regions or domains are defined in many papers: Kabat Sequences of Proteins of Immunological Interest (NationalInstitutes of Health, Bethesda Md (1987 and 1991)); Chothia&Lesk J. Mol.Biol. 1987; 196:901-917; Chothia et al., Nature 1989; 342:878-883; Ehrenmann, Francois, Quentin Kaas, and Marie-PauleLefranc. "IMGT / 3Dstructure-DB andIMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies,T cell receptors, MHC, IgSF and MhcSF." Nucleic acids research 2009; 38(suppl_1): D301-D307.

[0026] As used herein, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by Ala or A, glycine can be represented by Gly or G, valine can be represented by Val or V, leucine can be represented by Leu or L, isoleucine can be represented by Ile or I, proline can be represented by Pro or P, phenylalanine can be represented by Phe or F, tyrosine can be represented by Tyr or Y, tryptophan can be represented by Trp or W, serine can be represented by Ser or S, threonine can be represented by Thr or T, cysteine ​​can be represented by Cys or C, methionine can be represented by Met or M, asparagine can be represented by Asn or N, glutamine can be represented by Gln or Q, aspartic acid can be represented by Asp or D, glutamic acid can be represented by Glu or E, lysine can be represented by Lys or K, arginine can be represented by Arg or R, and histidine can be represented by His or H.

[0027] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and its antigen.

[0028] In the present invention, primers are also used to perform PCR amplification on the nucleotide sequence encoding the antibody. In the primer sequence, some sites only involve a single base, such as any one of adenine (A), guanine (G), cytosine (C) and thymine (T), while some sites involve a combination of two, three or four bases. In this case, these bases are called degenerate bases of each other, which are mainly determined based on the degeneracy of the codon. Degenerate bases can be represented by the letters R, Y, M, K, S, W, H, B, V, D, and N, wherein R represents A / G, Y represents C / T, M represents A / C, K represents G / T, S represents C / G, W represents A / T, H represents A / T / C, B represents G / T / C, V represents G / A / C, D represents G / A / T, and N represents A / T / C / G.

[0029] As mentioned above, the present invention aims to provide an anti-African swine fever virus antibody with high specificity and high sensitivity. As mentioned above, the present invention uses the p30 protein of the African swine fever virus as an antigen protein, and screens out anti-African swine fever virus antibodies with biological activity and strong antigen binding ability based on phage display technology and ELISA method.

[0030] Therefore, in the first aspect, the present invention provides an anti-African swine fever virus antibody, the antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a heavy chain complementary determining region V having an amino acid sequence of SEQ ID NO: 1-3, respectively. H CDR1, V H CDR2 and V HCDR3, the light chain variable region includes a light chain complementary determining region V having an amino acid sequence of SEQ ID NO: 4-6, respectively. L CDR1, V L CDR2 and V L CDR3.

[0031] Those skilled in the art understand that the specific binding of an antibody is mainly determined by the complementarity determining regions (CDRs) of the heavy and light chain variable regions. Therefore, the framework regions (FRs) of the antibodies of the present invention are relatively conservative. The amino acid sequence of the FR used in the variable region of the antibody of the present invention can be the amino acid sequence of the original FR as the source, or it can be a different amino acid sequence obtained by performing one or more amino acid substitutions, deletions, additions and / or insertions on the amino acid sequence of the original FR. The structure used to support the CDR or CDR group of the present invention generally belongs to the antibody heavy chain or light chain sequence or a major part thereof, wherein the CDR or CDR group is located in the same region as the naturally occurring V sequence encoded by the rearranged immunoglobulin gene. H and V L The CDR or CDR group of the antibody variable domain corresponds to the position of the antibody variable domain.

[0032] As an example, each framework region (FR) may have the following sequence:

[0033] HFR1 (heavy chain framework region 1, SEQ ID NO: 11): EVQVVQSGAELMKPGASVKISCKATGYTF

[0034] HFR2 (heavy chain framework region 2, SEQ ID NO: 12): WVKQRPGHGLEWIGEILP

[0035] HFR3 (heavy chain framework region 3, SEQ ID NO: 13): GKATFTADTSSNTAYMQLSSLTSEDSAVYYCAR

[0036] HFR4 (heavy chain framework region 4, SEQ ID NO: 14): YFDYWGQGTTLTVSL

[0037] LFR1 (light chain framework region 1, SEQ ID NO: 15): QIVLTQSPAIMSASPGEKVTMIC

[0038] LFR2 (light chain framework region 2, SEQ ID NO: 16): WYQQKPRSSPKPWIS

[0039] LFR3 (light chain framework region 3, SEQ ID NO: 17): SGVPARFSGSGSGTSYSLTISSMEAEDVATYYCQQ

[0040] LFR4 (light chain framework region 4, SEQ ID NO: 18): TFGGGTKLEIK

[0041] In yet another specific embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown by SEQ ID NO:7.

[0042] In yet another specific embodiment, the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:8.

[0043] In yet another specific embodiment, the antibody is a single chain antibody (scFv) in which the heavy chain variable region and the light chain variable region are connected together by a linker peptide.

[0044] The connecting peptide is a flexible short peptide with a length of 10-25 amino acids, usually composed of glycine (Gly) and serine (Ser), with a certain elasticity and protease resistance. Its function is to connect VH and VL and maintain a certain elasticity to make V H and V L The functional regions can still pair after folding to form a monovalent antigen binding site.

[0045] The most common linker peptide is the more flexible (Gly4-Ser)3 (or (GGGGS)3). This is not only because Ser and Gly make the linker peptide flexible and resistant to protease cleavage, but also increase the solubility of scFv.

[0046] In a further preferred embodiment, the connecting peptide is (GGGGS) n , where n is 2-5.

[0047] In a further preferred embodiment, the connecting peptide is (GGGGS)3.

[0048] In another specific embodiment, the amino acid sequence of the anti-African swine fever virus antibody is shown by SEQ ID NO: 9:

[0049] EVQVVQSGAELMKPGASVKISCKATGYTFSSYWIEWVKQRPGHGLEWIGEILPGSGSTNYNEKFKGKATFTADTSSNTAYMQLSSSLTSEDSAVYYCARYYGSNYFDYWGQGTTLTVSLGG GGSGGGGSGGGGSQIVLTQSPAIMSASPGEKVTMICSVSSSVSFMYWYQQKPRSSPKPWISLTSNLASGVPARFSGSGSGTSYSLTISSMEAEDVATYYCQQWSSSPPTFGGGTKLEIK.

[0050] As mentioned above, the anti-ASFV single-chain antibody of the present invention can specifically bind to the ASFV p30 protein. The p30 protein is a structural protein of ASFV, encoded by the CP204L gene, which can appear in the early stage of viral infection, induce the production of neutralizing antibodies in infected animals, and is one of the most antigenic proteins in ASFV. Therefore, the anti-ASFV single-chain antibody that specifically binds to the p30 protein of the present invention can be used for the early detection and diagnosis of ASFV infection, thereby providing technical support for the establishment of ASFV serological clinical diagnostic methods and the prevention and control of epidemics.

[0051] In a second aspect, a nucleic acid molecule is provided, which encodes the anti-African swine fever virus antibody described in the first aspect.

[0052] For those skilled in the art, knowing the amino acid sequence of a certain protein or polypeptide, such as the anti-ASFV antibody of the present invention, it is well within their ability to determine its nucleic acid coding sequence. In addition, in order to obtain a monoclonal antibody by recombinant means, the nucleic acid molecule can be cloned into a vector, and the vector can be further introduced into an expression cell to express the antibody protein using the expression cell.

[0053] In the third aspect, a vector is provided, which comprises the nucleic acid molecule described in the second aspect.

[0054] In a specific embodiment, the vector can be a plasmid vector.

[0055] In yet another specific embodiment, the vector may be a prokaryotic vector, such as pET-32a, pET-28a, and the like.

[0056] In a preferred embodiment, the vector may be a pET-32a vector.

[0057] In a fourth aspect, an expression cell is provided, which comprises the nucleic acid molecule described in the second aspect or the vector described in the third aspect.

[0058] The expression cell is prepared by introducing the above-mentioned nucleic acid molecule or the above-mentioned vector into a host cell by molecular biological methods well known to those skilled in the art.

[0059] In a specific embodiment, the expression cell may be a competent Escherichia coli cell, such as BL21 (DE3), Rosetta competent cell, etc.

[0060] In the fifth aspect, provided is the use of the anti-African swine fever virus antibody described in the first aspect in the preparation of a detection agent for detecting African swine fever virus.

[0061] In a specific embodiment, the anti-African swine fever virus antibody of the present invention specifically binds to the p30 protein of the African swine fever virus to detect the African swine fever virus, thereby detecting African swine fever, especially African swine fever in the early stages.

[0062] In a specific embodiment, the detection is performed by any one or more of immunochromatography, enzyme-linked antibody assay (ELISA), chemiluminescence, and electrochemiluminescence.

[0063] In yet another specific embodiment, the detection can be a direct method, an indirect method, a sandwich method, and a competitive method.

[0064] In a preferred embodiment, the immunochromatography includes but is not limited to fluorescent microsphere immunochromatography, colloidal gold immunochromatography, colored latex microsphere-based immunochromatography, time-resolved fluorescent microsphere immunochromatography, magnetic microsphere immunochromatography and quantum dot immunochromatography.

[0065] In the context of the present invention, the anti-African swine fever virus antibody can be used as a coating antibody. For example, the anti-African swine fever virus antibody of the present invention is combined with a solid phase such as a solid support. There is no particular limitation on the solid support used in the detection method of the present invention, which can be a porous or non-porous material, such as magnetic beads, latex microspheres, fluorescent microspheres, microtiter plates, nitrocellulose membranes, microfluidic chips, etc.

[0066] Without wishing to be bound by theory, the anti-African swine fever virus antibody of the present invention can also be used as a labeled antibody. For example, the anti-African swine fever virus antibody can be combined with magnetic beads, microspheres, enzymes, fluorescent dyes, biotin, streptavidin, quantum dots, colloidal gold, etc.

[0067] In a sixth aspect, a method for detecting African swine fever virus is provided. The method is used for non-diagnostic purposes or diagnostic purposes, and comprises the step of using the anti-African swine fever virus antibody described in the first aspect.

[0068] As mentioned above, the detection is performed by immunochromatography, enzyme-labeled antibody method (ELISA), chemiluminescence method, and electrochemiluminescence method. The immunochromatography method may include, but is not limited to, fluorescent microsphere immunochromatography, colloidal gold immunochromatography, immunochromatography based on colored latex microspheres, time-resolved fluorescent microsphere immunochromatography, magnetic microsphere immunochromatography, and quantum dot immunochromatography. Those skilled in the art can select the detection according to their needs, and the present invention is not particularly limited to this. In addition, the detection can be a direct method, an indirect method, a sandwich method, and a competitive method.

[0069] Also without wishing to be bound by theory, those skilled in the art will appreciate that the non-diagnostic detection methods of the present invention may include, but are not limited to, scientific research, quarantine testing, and the like.

[0070] In the seventh aspect, a kit for detecting African swine fever virus is provided, comprising the anti-African swine fever virus antibody described in the first aspect and instructions for use for guiding how to detect African swine fever virus.

[0071] In a specific embodiment, the anti-African swine fever virus antibody of the present invention specifically binds to the p30 protein of the African swine fever virus to detect the African swine fever virus, thereby detecting African swine fever, especially African swine fever in the early stages.

[0072] The kits according to the present invention and any exemplary formats thereof can be used and optimized in automated and semi-automated systems. Example

[0073] In the following examples, the preparation method of the antibody of the present invention and the characterization of related properties are shown. Unless otherwise specified, the test methods used are all conventional methods, and unless otherwise specified, the test materials used in the following examples are all purchased from conventional reagent stores. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by technicians in the technical field of the present invention.

[0074] It should be noted that the terms used in the specification of the present invention are only for the purpose of describing specific embodiments, and are not intended to limit the present invention. The above summary of the invention and the detailed description below are only for the purpose of specifically explaining the present invention, and are not intended to limit the present invention in any way. Without departing from the spirit and purpose of the present invention, the scope of the present invention is determined by the attached claims.

[0075] Material

[0076] Experimental animals: Balb / c mice, purchased from Guangdong Medical Experimental Animal Center

[0077] Strains and reagents:

[0078] Competent state E. coli JM109, PrimeSTAR® HS DNA Polymerase, RNase-free Water, DL2,000 DNA Marker, and 6× Loading Buffer were all purchased from Takara Biotech;

[0079] Competent BL21 (DE3) was purchased from Beijing Quanshijin Biotechnology Co., Ltd.;

[0080] Trizol, nickel affinity chromatography resin, DNA fragment recovery kit, and plasmid extraction kit were purchased from OMEGA;

[0081] Molecular biology reagents were purchased from Sigma.

[0082] Example 1: Total RNA extraction and cDNA synthesis from mouse spleen cells

[0083] Mice were immunized with an emulsion containing 100 μg of ASFV p30 protein antigen (SEQ ID NO: 10: MDFILNISMKMEVIFKTDLRSSSQVVFHAGSLYNWFSVEIINSGRIVTTAIKTLLSTVKYDIVKSARIYAGQGYTEHQAQEEWNMILHVLFEEETESSASSENIHEKNDNETNECTSSFETLFEQEPSSEVPKDSKLYMLAQKTVQHIEQYGKAPDFNKVIRAHNFIQTIYGTPLKEEEKEVVRLMVIKLLKKISFYLTYI) and Freund's complete adjuvant in PBS. Three weeks later, mice were immunized again with an emulsion containing the same amount of antigen and incomplete Freund's adjuvant. When the antibody titer was high enough as determined by ELISA, the mice were anesthetized to death and the spleen was removed under sterile conditions. The residual fat and connective tissue were removed and the spleen was quickly cut into pieces and divided into 1.5 ml centrifuge tubes treated with DEPC water. Add 1mL Trizol, mix, and stand at 4℃ for 5min; add 250μl chloroform, mix, stand at 4℃ for 10min, centrifuge at 12000r / min, 4℃ for 15min; aspirate 450μl supernatant, add an equal amount of isopropanol, stand at -20℃ for 30min, centrifuge at 12000r / min, 4℃ for 15min; discard the supernatant, add 1mL 75% ethanol to the precipitate, centrifuge at 12000r / min, 4℃ for 5min; place the precipitate in a fume hood for 10min to dry; the precipitate dissolved in 25μL RNase-free water is the total mRNA harvested. According to the steps in the RNA reverse transcription kit product manual, reverse transcribe the extracted RNA into cDNA and place it at -80o C. Store in refrigerator for later use.

[0084] Example 2: Fusion of scFv

[0085] Using spleen lymphocyte cDNA as template, multiple pairs of primers were used to amplify V H and V L The specific steps are as follows: Design mouse V H Variable region genes and V L (V κ ) Variable region gene specific upstream and downstream primers were used for the first step V H and V L PCR amplification, where V H There are 12 pairs of primers (4 upstream primers and 3 downstream primers), V L There are 12 pairs of primers (4 upstream primers and 3 downstream primers), as shown in Table 1. The PCR amplification program is: 98℃ 2min, 98℃ 10s, 52℃ 5s, 72℃ 30s, 30 cycles, 72℃ 10min; the amplified product is electrophoresed, and the product of about 300 bp is purified and collected, which is the amplified target product. Figure 1 shown.

[0086] Table 1: Mouse V H Variable region genes and V L (V κ ) Upstream and downstream primers for PCR amplification of variable region genes

[0087]

[0088] The heavy chain variable region gene V H and light chain variable region gene V L The scFv gene was assembled and the PCR amplification program was: 98°C for 2 min, 98°C for 10 s, 54°C for 5 s, 72°C for 30 s, 30 cycles, and 72°C for 10 min; after ligation, V L -linker-V H .

[0089] Example 3: Construction of ScFv single-chain antibody library

[0090] The PCR product was purified by gel recovery, and the fused mouse scFv fragment was inserted into the linearized phagemid vector pComb3MQ-P3 / WT (reference patent number ZL202310039309.0) through homologous recombination reaction, and the phagemid was transformed into competent cells (E.coli JM109) under the conditions of 2.5kV and 800Ω. After electroporation, 1 mL of 37℃ preheated SOC culture medium was added to resuspend, and washed several times, and the volume was transferred to a 50 mL centrifuge tube and incubated at 37 o C, 200 r / min shaking culture for 1 h. Take 100 μL of bacterial solution for gradient dilution, select the appropriate dilution to drip on LB / Amp plate, place it in a biochemical incubator at 37°C for overnight culture, count the number of monoclonal clones on the resistance plate and calculate the library capacity of the antibody library accordingly. Randomly pick 12 clones and identify whether the complete single-chain antibody gene in these 12 clones is connected to the vector sequence, and sequence the successfully connected clones (i.e. positive clones). Expand the remaining bacterial solution and wait until the bacterial solution OD 600 = 0.5, add helper phage M13K07, 37 o After 30 min of infection with C, continue to shake the bacteria for 1 h, remove the culture medium, replace it with an equal volume of 2YT medium containing Amp+ (100μg / mL), Kan (50μg / mL) and IPTG (0.1 mmol / mL), and shake the bacteria overnight. Centrifuge at 10000g for 10 min, collect the supernatant, add 1 / 4 volume of PEG8000 / NaCl, place at 4℃ for 1~2 h, and centrifuge at 12000g to obtain the recombinant phage antibody library precipitate; add an appropriate amount of sterile PBT solution to resuspend the precipitate, centrifuge at 12000g at 4℃ for 10 min, and obtain the supernatant, which is the antibody library. The phage was separated and purified by PEG8000 / NaCl precipitation method to obtain the immune library, and its index statistics are shown in Table 2 below. Adjust the phage concentration and freeze it at -80℃ for later use.

[0091] Table 2: Statistics of immune library indicators

[0092]

[0093] Example 4: Screening of phage antibody display library and identification of positive antibodies

[0094] The specific anti-ASFV antibodies were screened using solid phase screening. The specific method is as follows:

[0095] (1) Add ASFV p30 protein as an antigen to a 96-well plate at 500 ng / well. Set up the same number of control wells and add an equal volume of coating solution. o C pack overnight.

[0096] (2) Discard the coating solution in the 96-well plate, add 200 μL of 0.5% BSA blocking solution to each well, and incubate on a shaker at room temperature for 1.5 h.

[0097] (3) Cultivating host bacteria: Select TG1 host bacteria in good condition and inoculate them into an appropriate volume of fresh 2YT medium. Cultivate the culture at 37°C and 220 rpm with shaking.

[0098] (3) Discard the blocking solution in the 96-well plate and wash four times with 200 μL PBST, 200 μL per well.

[0099] (4) Add phage antibody library, 100 μL / well, and incubate at room temperature for 2 h.

[0100] (5) Real-time monitoring of host bacteria OD 550 When the value is about 0.1~0.15, take it out from the shaker and place it at room temperature for later use.

[0101] (6) Discard the antibody library, add 200 μL PBST to each well, and wash 10 times.

[0102] (7) Add 100 mM HCl, 100 μL / well, incubate at room temperature for 5 min, elute the bound recombinant phage, and combine and collect into a clean EP tube.

[0103] (8) Add 1 M Tris-HCl, pH 8.0, corresponding to 40 μL / well, to make the pH of the mixture neutral.

[0104] (9) Add the phage obtained in the previous step to 10 times the volume of TG1 bacteria and incubate at 37°C, 200 rpm for 30 min.

[0105] (10) Take 50 μL of bacterial solution and perform 10-fold serial dilutions. Select the bacterial solution with the appropriate dilution and spread it on the LB / Amp plate. Incubate it at 37°C overnight.

[0106] (11) Add helper phage (final concentration 10 10 phage / mL), 37°C, 200 rpm, incubate for 1 h.

[0107] (12) Transfer the above bacterial solution into 25 times the volume of 2YT / Amp / Kan / IPTG medium and incubate overnight at 37°C, 200 rpm.

[0108] (13) The next day, collect the antibody library Phage, dilute it with PBT solution, and measure the OD 268 Determine the concentration (OD 268=1.0, the concentration of Phage is about 5.0×10 12 phage / mL).

[0109] (14) Repeat the above screening process for the obtained Phage, and determine whether it is enriched by comparing the colony counts in the antigen wells with those in the control wells.

[0110] When obvious enrichment is observed, the progeny phage library corresponding to this round is used to infect the host bacteria, and the resistance plate is coated. 96 single clones / library are randomly selected for culture, and the supernatant of the overnight culture is collected. The positive single clones are identified by Phage ELISA experiment. The specific steps are as follows:

[0111] (1) Prepare 2YT / Amp / Kan medium and add helper phage (final concentration: 10 10 phage / mL).

[0112] (2) Add 450 μL of the above culture medium to each well of a 96-deep-well plate, pick a single clone on the enriched LB / Amp or LB / Amp / Kan plate, and place the 96-deep-well plate on a shaker at 200 rpm and 37°C for overnight culture.

[0113] (3) Use coating solution to dilute the antigen protein to an appropriate concentration and add 100 μL / well to the ELISA plate. At the same time, use coating solution to coat another ELISA plate as a negative control and incubate overnight at 4°C.

[0114] (4) Invert the ELISA plate and discard the supernatant. Add 200 μL of 0.5% BSA blocking solution to each well and incubate at room temperature for 1.5 h.

[0115] (5) Take out the 96-well deep culture plate and centrifuge at 4000 rpm for 10 min.

[0116] (6) Remove the blocking solution from the ELISA plate, wash it three times with PBST, add 50 μL of the culture supernatant from the above 96-well deep-well plate, and incubate at room temperature for 2 h.

[0117] (7) Wash four times with PBST, add diluted HRP-M13 antibody, 100 μL / well, and incubate at room temperature for 1 h.

[0118] (8) Wash four times with PBST, add 100 μL / well of TMB, incubate at room temperature or 37°C in the dark for 10 min, and observe the color change until a clear color reaction is observed.

[0119] (9) Add an equal volume of 1 M hydrochloric acid or sulfuric acid solution (100 μL / well) to terminate the reaction (the reaction solution changes from blue to yellow).

[0120] (10) Within 30 min after terminating the reaction, measure the absorbance at 450 nm using an enzyme reader.

[0121] Finally, based on the OD value ratio of the ELISA positive wells to the control wells (a ratio ≥ 3 was considered positive), the positive monoclonal clones were selected for sequencing.

[0122] The present invention finally screened out a positive clone (also labeled as S17) with a complete scFv, and the complementary determining region sequences of the heavy chain and light chain are shown in Table 3 below.

[0123] Table 3: Complementarity determining region sequences of the heavy and light chains of single-chain antibody S17

[0124]

[0125] In addition, the amino acid sequences of the heavy chain variable region and the light chain variable region of the scFv antibody are shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively, and the amino acid sequence of the connecting peptide connecting the heavy chain variable region and the light chain variable region is (GGGGS) 3 .

[0126] Example 5: Prokaryotic expression and purification of single-chain antibody

[0127] The target scFv sequence was connected to the pET-32a vector, and the resulting recombinant pET-32a-scFv vector was then transformed into BL21 competent cells and cultured in LB Amp+ The culture was shaken at 220 r / min at 37°C for 1 h, and then the bacterial solution was inoculated into LB at a ratio of 1:100. Amp+ When the OD value of the bacterial solution reached about 0.6, 1 mmol / L isopropyl β-D-thiogalactoside (IPTG) was added and induced at 16°C and 220 r / min for 10 hours. The bacteria were collected and resuspended in PBS, then ultrasonically disrupted in an ice bath, centrifuged and the supernatant was collected, and finally purified and recovered by nickel affinity chromatography. The target protein was identified by SDS-PAGE, and a clear specific band at 27 kDa was observed, such as Figure 2 As shown, this indicates that the S17 single-chain antibody was successfully purified.

[0128] Example 6: ELISA to verify the antibody activity of single-chain antibodies

[0129] In order to verify the binding activity of S17 single-chain antibody with ASFV p30 protein, the reaction activity was identified using purified S17 antibody as coating substrate. Specifically, the purified ScFv single-chain antibody was coated on the test plate in a ratio of 1:10. After blocking and rinsing, 100 ng 50 μL of p30 antigen was added, incubated in a 37°C incubator for 30 minutes, washed 4 times with PBST washing solution, patted dry, and then 50 μL of another p30 enzyme-labeled monoclonal antibody diluted 1:15000 was added, incubated at 37°C for 30 minutes, washed 4 times with PBST washing solution, 50 μL of TMB substrate solution was added, incubated at 37°C in the dark for 10 minutes, 50 μL of sulfuric acid stop solution was added, and the absorbance at 450nm was measured with an enzyme reader. Results Figure 3 As shown, when the concentration of S17 was 250 ng / well or above, the S17 single-chain antibody had a strong reactivity with p30.

[0130] Example 7: Verification of single-chain antibody specificity

[0131] The purified S17 single-chain antibody was coated on the ELISA test plate at 250 ng / well. After blocking and washing, 100 ng of African swine fever virus p30 protein, p54 protein, p72 protein, porcine circovirus Cap protein and swine fever virus E2 protein were added respectively, incubated at 37°C for 30 min, washed 4 times with PBST washing solution, and then the corresponding enzyme-labeled monoclonal antibody was added respectively, incubated at 37°C for 30 min, washed 4 times with PBST washing solution, 50 μL of TMB substrate solution was added, incubated at 37°C in the dark for 10 min, 50 μL of sulfuric acid stop solution was added, and the absorbance at 450 nm was measured with an enzyme reader. The results are as follows Figure 4 As shown, S17 is reactive only with p30 but not with other proteins, indicating that the S17 single-chain antibody has strong specificity.

[0132] Sequence Listing:

[0133] SEQ ID NO: 1 (V H CDR1): SSYWIE

[0134] SEQ ID NO: 2 (V H CDR2):GSGSTNYNEKFK

[0135] SEQ ID NO: 3 (V H CDR3): YYGSN

[0136] SEQ ID NO: 4 (V L CDR1):SVSSSVSFMY

[0137] SEQ ID NO: 5 (VL CDR2):LTSNLA

[0138] SEQ ID NO: 6(V L CDR3):WSSSPP

[0139] SEQ ID NO: 7(V H ): EVQVVQSGAELMKPGASVKISCKATGYTFSSYWIEWVKQRPGHGLEWIGEILPGSGSTNYNEKFKGKATFTADTSSNTAYMQLSSLTSEDSAVYYCARYYGSNYFDYWGQGTTLTVSL

[0140] SEQ ID NO: 8(V L ):QIVLTQSPAIMSASPGEKVTMICSVSSSVSFMYWYQQKPRSSPKPWISLTSNLASGVPARFSGSGSGTSYSLTISSMEAEDVATYYCQQWSSSPPTFGGGTKLEIK

[0141] SEQ ID NO:9 EVQVVQSGAELMKPGASVKISCKATGYTFSSYWIEWVKQRPGHGLEWIGEILPGSGSTNYNEKFKGKATFTADTSSNTAYMQLSSLTSEDSAVYYCARYYGSNYFDYWGQGTTLTVSLGGGGSGGGGSGGGGSQIVLTQSPAIMSASPGEKVTMICSVSSSVSFMYWYQQKPRSSPKPWISLTSNLASGVPARFSGSGSGTSYSLTISSMEAEDVATYYCQQWSSSPPTFGGGTKLEIK

[0142] SEQ ID NO: 10(P30):MDFILNISMKMEVIFKTDLRSSSQVVFHAGSLYNWFSVEIINSGRIVTTAIKTLLSTVKYDIVKSARIYAGQGYTEHQAQEEWNMILHVLFEEETESSASSENIHEKNDNETNECTSSFETLFEQEPSSEVPKDSKLYMLAQKTVQHIEQYGKAPDFNKVIRAHNFIQTIYGTPLKEEEKEVVRLMVIKLLKKISFYLTYI

[0143] SEQ ID NO: 11(HFR1):EVQVVQSGAELMKPGASVKISCKATGYTF

[0144] SEQ ID NO: 12(HFR2):WVKQRPGHGLEWIGEILP

[0145] SEQ ID NO: 13(HFR3):GKATFTADTSSNTAYMQLSSLTSEDSAVYYCAR

[0146] SEQ ID NO: 14(HFR4):YFDYWGQGTTLTVSL

[0147] SEQ ID NO: 15(LFR1):QIVLTQSPAIMSASPGEKVTMIC

[0148] SEQ ID NO: 16(LFR2):WYQQKPRSSPKPWIS

[0149] SEQ ID NO: 17(LFR3):SGVPARFSGSGSGTSYSLTISSMEAEDVATYYCQQ

[0150] SEQ ID NO: 18(LFR4):TFGGGTKLEIK

Claims

1. An anti-African swine fever virus antibody, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises heavy chain complementary determining regions VH CDR1, VH CDR2 and VHCDR3 with amino acid sequences of SEQ ID NOs: 1-3, respectively, and the light chain variable region comprises light chain complementary determining regions VL CDR1, VL CDR2 and VL CDR3 with amino acid sequences of SEQ ID NOs: 4-6, respectively.

2. The anti-African swine fever virus antibody according to claim 1, wherein The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:7; the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

8.

3. The anti-African swine fever virus antibody according to claim 1 or 2, wherein The antibody is a single-chain antibody in which the heavy chain variable region and the light chain variable region are linked together by a linker peptide.

4. The anti-African swine fever virus antibody according to claim 3, wherein The connecting peptide is (GGGGS)n, wherein n is 2-5.

5. The anti-African swine fever virus antibody according to claim 4, wherein The amino acid sequence of the anti-African swine fever virus antibody is shown in SEQ ID NO:

9.

6. A nucleic acid molecule encoding the anti-African swine fever virus antibody according to any one of claims 1 to 5. A vector comprising the nucleic acid molecule according to claim 6 .

8. The carrier according to claim 7, wherein The vector is a prokaryotic vector. 9 . An expression cell comprising the nucleic acid molecule of claim 6 or the vector of claim 7 or 8 .

10. The expression cell according to claim 9, wherein The expression cells are competent Escherichia coli cells.

11. Use of the anti-African swine fever virus antibody according to any one of claims 1 to 5 in the preparation of a detection agent for detecting African swine fever virus.

12. The use according to claim 11, wherein The detection is performed by immunochromatography, enzyme-labeled antibody method, and chemiluminescence method.

13. The use according to claim 11, wherein The detection is performed by electrochemiluminescence.

14. A method for detecting African swine fever virus for non-diagnostic purposes, comprising the step of using the anti-African swine fever virus antibody according to any one of claims 1 to 5.

15. The method according to claim 14, wherein: The detection is performed by immunochromatography, enzyme-labeled antibody method, and chemiluminescence method.

16. The method according to claim 14, wherein: The detection is performed by electrochemiluminescence.

17. A kit for detecting African swine fever virus, the kit comprising the anti-African swine fever virus antibody according to any one of claims 1 to 5 and instructions for use for guiding how to detect African swine fever virus.

Citation Information

Patent Citations

  • A method for preparing a specific single-chain antibody against African swine fever virus

    CN116444652B

  • A Monoclonal Antibody Capable Of Competing With Positive Serum For Binding To African Swine Fever Virus B646L Antigen And The Application Thereof

    AU2020103187A4

  • Monoclonal antibody for resisting African swine fever virus as well as derivative product and application thereof

    CN115850452A